Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

9.10
-0.2800-2.99%
Post-market: 9.100.00000.00%19:48 EDT
Volume:3.93M
Turnover:35.98M
Market Cap:1.43B
PE:-2.88
High:9.48
Open:9.35
Low:9.05
Close:9.38
52wk High:10.94
52wk Low:4.16
Shares:157.00M
Float Shares:107.00M
Volume Ratio:1.66
T/O Rate:3.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1619
EPS(LYR):-3.1619
ROE:-45.73%
ROA:-24.36%
PB:1.87
PE(LYR):-2.88

Loading ...

U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR

Reuters
·
Feb 17

Earning Preview: Vir Biotechnology, Inc. revenue is expected to increase by 184.80%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 16

Vir Biotechnology Inc. to Host Conference Call on Financial Results

Reuters
·
Feb 10

Vir Biotechnology Price Target Maintained With a $14.00/Share by Needham

Dow Jones
·
Feb 09

Barclays Keeps Their Buy Rating on Vir Biotechnology (VIR)

TIPRANKS
·
Feb 04

Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares

Reuters
·
Feb 04

Vir Biotechnology Reports Positive Data in Chronic Hepatitis Delta Trial

MT Newswires Live
·
Jan 14

H.C. Wainwright says Vir’s SOLSTICE 96-week data reinforces best-in-class

TIPRANKS
·
Jan 13

Vir Biotechnology updates on chronic hepatitis delta and oncology programs

TIPRANKS
·
Jan 13

BRIEF-Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones

Reuters
·
Jan 12

Vir Biotechnology Reports 88% Undetectable HDV RNA at 96 Weeks with Tobevibart and Elebsiran Combination Therapy

Reuters
·
Jan 12

Vir Biotechnology Inc: Positive, Updated Phase 2 Solstice Data Showed Combination of Tobevibart and Elebsiran Is Well Tolerated

THOMSON REUTERS
·
Jan 12

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

THOMSON REUTERS
·
Jan 12

Vir Biotechnology CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 06

Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares

Reuters
·
Jan 06

Vir Biotechnology Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 30, 2025

Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer

Reuters
·
Dec 17, 2025

Vir Biotechnology Grants Norgine Exclusive License for Hepatitis Delta Treatment in Europe, Australia, and New Zealand

Reuters
·
Dec 17, 2025

Vir Biotechnology Inc - Norgine to Contribute 25% of Eclipse Program Costs

THOMSON REUTERS
·
Dec 17, 2025

Vir Biotechnology- Expects Current Cash, Cash Equivalents and Investments Will Be Extended Into Q4 2027

THOMSON REUTERS
·
Dec 17, 2025